Telix PharmaceuticalsTLX +6.76%50 Gross Margin % is 52.68% as of Dec. 2025, which is 7% below its 10-year median of 56.76. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $27.71 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 738 Biotechnology companies, Telix Pharmaceuticals ranks worse than 57.99% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Telix Pharmaceuticals had a gross margin of 52.68% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Telix Pharmaceuticals Gross Margin % Related Terms
Telix Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLX vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Telix Pharmaceuticals (TLX) has a Gross Margin % of 52.68% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Telix Pharmaceuticals and its competitors. This is near median its historical median of 56.76. Over the past decade, Telix Pharmaceuticals' Gross Margin % has ranged from 27.01 to 65.08. According to the industry distribution chart, Telix Pharmaceuticals ranks #428 out of 738 companies in the Biotechnology industry, placing it in the top 58%.
Is Telix Pharmaceuticals' Gross Margin % too high?
Telix Pharmaceuticals' current Gross Margin % of 52.68% is near median its 10-year median of 56.76. Over the past 10 years, this metric has ranged from a low of 27.01 to a high of 65.08. The Biotechnology industry median Gross Margin % is 60.94. Telix Pharmaceuticals' value of 52.68% is 13.6% below this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #428 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #428 out of 738 companies for Gross Margin %. This places Telix Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 60.94. Telix Pharmaceuticals' value of 52.68% is 13.6% below this benchmark. Historically, Telix Pharmaceuticals' own Gross Margin % has ranged from 27.01 to 65.08 over the past decade. While the company's 10-year median is 56.76 vs. the industry median of 60.94, Telix Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current Gross Margin % of 52.68% is 13.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current Gross Margin % is 52.68%, which is near median its own 10-year median of 56.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $27.71, compared to a current price of $10.90 — trading 60.7% below its estimated fair value. The current Gross Margin % is 52.68%, which is near median its 10-year median of 56.76 and 13.6% below the Biotechnology industry median of 60.94. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Gross Margin % is 52.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $10.90 is trading 60.7% below its estimated GF Value™ of $27.71.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
Gross Margin %: 52.68% (near median its 10-year median of 56.76)
GF Value™: $27.71 vs. price of $10.90 (60.7% below fair value)
Industry Position: 13.6% below the Biotechnology median (#428 of 738)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
